Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...
Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 - - Advancement reflects continued execution of ...
- Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ - ...
Despite the White House’s claim that the platform offers the world’s lowest prices on prescriptions, Democrats on the House Energy and Commerce Committee released a report saying “for nearly half of ...
Some residents in the Philadelphia suburb of Quakertown are calling for the police chief to resign after a scuffle between police and students protesting ICE policies left several juveniles in ...
When new safety information for medicines is identified, the Therapeutic Goods Administration (TGA) works with the sponsors to update Product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results